Day One Biopharmaceuticals Inc (NASDAQ: DAWN) established initial surge of 25.21% at $9.14, as the Stock market unbolted on Wednesday, before settling in for the price of $7.3 at the close. Taking a more long-term approach, DAWN posted a 52-week range of $5.64-$16.76.
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -38.09%. Meanwhile, its Annual Earning per share during the time was -38.09%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -0.76%. This publicly-traded company’s shares outstanding now amounts to $102.68 million, simultaneously with a float of $74.36 million. The organization now has a market capitalization sitting at $749.53 million. At the time of writing, stock’s 50-day Moving Average stood at $7.31, while the 200-day Moving Average is $7.80.
Day One Biopharmaceuticals Inc (DAWN) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Day One Biopharmaceuticals Inc industry. Day One Biopharmaceuticals Inc’s current insider ownership accounts for 27.40%, in contrast to 75.57% institutional ownership. According to the most recent insider trade that took place on Aug 18 ’25, this organization’s COO and CFO sold 4,106 shares at the rate of 6.77, making the entire transaction reach 27,786 in total value, affecting insider ownership by 278,000. Preceding that transaction, on Aug 18 ’25, Company’s Gen Counsel & Secretary sold 4,365 for 6.77, making the whole transaction’s value amount to 29,538. This particular insider is now the holder of 54,858 in total.
Day One Biopharmaceuticals Inc (DAWN) Earnings and Revenue Records
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Let’s observe the current performance indicators for Day One Biopharmaceuticals Inc (DAWN). It’s Quick Ratio in the last reported quarter now stands at 8.55. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.61.
In the same vein, DAWN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.49, a figure that is expected to reach -0.21 in the next quarter, and analysts are predicting that it will be -0.55 at the market close of one year from today.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Now, what If we examine the latest scores posted by [Day One Biopharmaceuticals Inc, DAWN]. During the last 5-days, its volume was better the volume of 1.41 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 52.21% While, its Average True Range was 78.36.
Raw Stochastic average of Day One Biopharmaceuticals Inc (DAWN) in the period of the previous 100 days is set at 80.30%, which indicates a major rise in contrast to 72.26% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.48 that was higher than 0.33 volatility it exhibited in the past 100-days period.
